M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Phase 2

Terminated

Conditions: Graft-versus-Host Disease

Interventions: Drug: Lenalidomide

First Posted Date: 2008-05-09

Last Posted Date: 2013-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00675441

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Palliative Care and Symptom Management for the Pediatric Oncology Patient

Completed

Conditions: Pediatric Cancers

Interventions: Behavioral: Focus Group - Parent/Caregiver
Behavioral: Focus Group - Pediatric Patient

First Posted Date: 2008-05-09

Last Posted Date: 2016-04-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00675467

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

INCB018424 in Patients With Advanced Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia

Interventions: Drug: INCB018424

First Posted Date: 2008-05-07

Last Posted Date: 2024-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00674479

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Not Applicable

Terminated

Conditions: Osteosarcoma

Interventions: Drug: Doxorubicin
Drug: Cisplatin
Drug: Methotrexate
Drug: Leucovorin
Behavioral: Questionnaire
Drug: Dexrazoxane
Procedure: Surgery
Drug: Ifosfamide
Drug: Gemcitabine
Drug: Sargramostim
Drug: Mesna

First Posted Date: 2008-05-07

Last Posted Date: 2014-09-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00673179

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Phase 1

Terminated

Conditions: Malignant Gliomas

Interventions: Drug: Irinotecan
Drug: Lenalidomide

First Posted Date: 2008-05-05

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00671801

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Rituximab
Drug: Cyclophosphamide (CTX)
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Methotrexate (MTX)
Drug: Cytarabine
Drug: G-CSF
Drug: Mesna
Drug: Pegylated asparaginase
Drug: Pegfilgrastim
Drug: Solumedrol

First Posted Date: 2008-05-05

Last Posted Date: 2020-12-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 220

Registration Number: NCT00671658

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

Completed

Conditions: Gynecologic Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-05-05

Last Posted Date: 2020-12-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 588

Registration Number: NCT00671827

Locations: 🇺🇸
MD Anderson Banner Arizona, Gilbert, Arizona, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Hysteroscopic Lymphatic Mapping for Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Procedure: Intraoperative Lymphatic Mapping

First Posted Date: 2008-05-05

Last Posted Date: 2016-05-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00671606

Locations: 🇺🇸
St. Luke's Episcopal Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Phase 2

Completed

Conditions: Burkitt's Lymphoma
Burkitt'S-like Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: G-CSF
Drug: Cytarabine
Drug: Methotrexate

First Posted Date: 2008-05-01

Last Posted Date: 2018-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00669877

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Long Term Minor Sibling Donor Well-Being

Terminated

Conditions: Disorder Related to Bone Marrow Transplantation
Blood Stem Cell Transplant Failure
Disturbance of Emotions Specific to Childhood and Adolescence
Transmission, Blood, Recipient/Donor
Sibling

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-04-28

Last Posted Date: 2012-04-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00667784

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy